Skip to content

Individual Psychotherapy for Cluster C Personality Disorders: A pragmatic RCT comparing time limited Psychodynamic, Affect Phobia and Schema Therapy

Individual Psychotherapy for Cluster C Personality Disorders: A pragmatic RCT comparing time limited Psychodynamic, Affect Phobia and Schema Therapy - I-FORCE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52837
Enrollment
264
Registered
2020-08-21
Start date
2020-10-23
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cluster C Personality Disorders persoonlijkheidsproblemen

Interventions

SPSP, APT and ST (50 sessions per condition) are offered twice a week in sessions of 50 minutes for the first four to five months. After that, session frequency decreases to once a week. All conditi

Sponsors

Arkin (Amsterdam)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Primary diagnoses: DSM-5 diagnosis cluster C PD or Otherwise specified PD with predominantly cluster C traits, operationalized as a minimum of 5 cluster C traits - Age 18-65 years - A written informed consent - Dutch literacy - The willingness and ability to participate in an individual treatment of 50 sessions in one year.

Exclusion criteria

Exclusion criteria: - (Subthreshold) cluster A or B PD - Having received SPSP, APT or ST in the previous year - Immediate intensive treatment or hospitalization is needed, e.g. acute suicidality - Severe psychiatric disorder requiring priority in treatment (autism spectrum disorder, psychotic symptoms/disorder, bipolar disorder) - Severe substance use disorder - IQ

Design outcomes

Primary

MeasureTime frame
Personality change (ADP-IV) will be the main outcome measure.

Secondary

MeasureTime frame
Secondary outcome measures are psychiatric symptoms, quality of life and costs from a societal perspective. Assessments will take place at baseline (after signing the Informed Consent), at the start of the treatment and at 1, 3, 6, 9, 12, 18, 24 and 36 months after the start of the treatment.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)